Track Cipla Ltd live share price with 52 week high and low, chart views, quick fundamentals, company profile, business segments, financial statements, ratios, pharma peer comparison, dividends, corporate actions and beginner-friendly investor FAQs.
Switch between 1 Day, 5 Day, 1 Month and 1 Year chart views. Chart data is fetched using the Yahoo Finance-compatible NSE symbol CIPLA.NS.
These quick numbers help beginners connect Cipla share price with market value, valuation, earnings, dividend yield and trading activity. Live feeds may be delayed, so verify important numbers from NSE, BSE and Cipla filings before making decisions.
This section uses the latest available data feed for selected profitability, growth and leverage indicators. If a field is unavailable, use Cipla annual reports and exchange filings for the latest audited figures.
Cipla Ltd is a global pharmaceutical company headquartered in Mumbai, India. The company focuses on making medicines more accessible across respiratory care, chronic therapies, acute care, anti-infectives, HIV/AIDS, urology, oncology, consumer health and other important treatment areas.
For customers and patients, Cipla is known for a broad portfolio of medicines and respiratory products used through doctors, hospitals, clinics and pharmacies. Product availability depends on country-level approvals and local regulations, so customers should rely on prescriptions and official product information.
For investors, Cipla is usually evaluated on India growth, North America product launches, respiratory franchise strength, complex generic approvals, regulatory compliance, research and development pipeline, margin stability, cash generation and capital allocation.
A pharmaceutical company like Cipla grows by launching medicines, expanding distribution, maintaining quality approvals, managing manufacturing costs and complying with strict healthcare regulations. Shareholders should understand that medicine businesses can face both growth opportunities and sudden regulatory or product-specific risks.
Cipla makes money by developing, manufacturing and selling pharmaceutical products in India and international markets. Its revenue comes from branded prescription medicines, trade generics, complex generics, respiratory devices and formulations, active pharmaceutical ingredients, consumer health products and selected institutional or tender-led businesses.
The company benefits when it can launch differentiated products, maintain strong doctor and pharmacy relationships, receive regulatory approvals on time, avoid major quality disruptions and protect margins despite pricing pressure. In generic pharmaceuticals, competition can be intense, so scale, compliance and product selection matter.
Important monitorables include India formulation growth, US product approvals, complex product pipeline, respiratory franchise performance, pricing pressure, currency impact, raw material costs, working capital, manufacturing quality status and free cash flow.
The table below explains Cipla business areas in plain language. Segment names and reporting categories can change, so verify the latest segment details from Cipla annual reports and official exchange filings.
| Business area | What it covers | What investors should monitor |
|---|---|---|
| India prescription and branded generics | Medicines sold through doctors, hospitals, pharmacies and distribution channels in India | Track growth in respiratory, chronic and acute therapies, pricing, volume growth and product launches |
| Trade generics and consumer health | Generic medicines and health products used by patients, pharmacies and families | Watch distribution strength, affordability, brand recall and regulatory compliance |
| North America | Generic and complex pharmaceutical products sold in the US and nearby markets | Monitor product approvals, price erosion, regulatory inspections, competition and launches |
| South Africa and global access | Medicines supplied across South Africa and access-focused international markets | Track tender business, currency movement and demand for essential medicines |
| Emerging markets and Europe | Pharmaceutical sales across selected international geographies | Watch country-level regulation, exchange rates, product registration and supply chain execution |
| Active pharmaceutical ingredients and other products | Inputs used in medicines and selected specialty opportunities | Monitor margin contribution, raw material prices and quality compliance |
The profit and loss statement helps investors understand revenue, operating profit and net profit trends. Pharma investors should look for steady revenue growth, healthy margins, R&D investment discipline and sustainable net profit growth.
| Particulars | Latest available |
|---|---|
| Total Revenue | Verify latest filing |
| Gross Profit | Verify latest filing |
| Operating Income | Verify latest filing |
| Profit Before Tax | Verify latest filing |
| Net Income | Verify latest filing |
Financial figures from third-party feeds may be delayed or incomplete. Verify audited annual and quarterly results from Cipla investor relations, NSE and BSE before using them for decisions.
The balance sheet shows assets, liabilities, equity, cash, inventory and debt. For a pharmaceutical company, a strong balance sheet can support R&D, product launches, acquisitions and regulatory remediation if needed.
| Particulars | Latest available |
|---|---|
| Total Assets | Verify latest filing |
| Total Liabilities | Verify latest filing |
| Shareholder Equity | Verify latest filing |
| Cash and Equivalents | Verify latest filing |
| Inventory | Verify latest filing |
| Short / Long Term Debt | Verify latest filing |
Verify the latest balance sheet, contingent liabilities and notes to accounts from official filings, especially after acquisitions, regulatory settlements or major product launches.
Cash flow shows how much cash the company generates from operations and how much it spends on investments, capital expenditure, financing and dividends. For Cipla, consistent operating cash flow supports manufacturing, research and development, dividend payments and future growth investments.
| Particulars | Latest available |
|---|---|
| Operating Cash Flow | Verify latest filing |
| Capital Expenditure | Verify latest filing |
| Investing Cash Flow | Verify latest filing |
| Financing Cash Flow | Verify latest filing |
| Dividends Paid | Verify latest filing |
| Change in Cash | Verify latest filing |
| Area | Why it matters | Investor monitorable |
|---|---|---|
| Respiratory franchise | Cipla is well known for inhalation and respiratory care products | Device quality, prescriptions, market share and regulatory approvals are important |
| Complex generics | Products that may require specialized development, manufacturing or regulatory work | Can improve margins, but approval timelines and competition are uncertain |
| Research and development | R&D supports new product filings, respiratory devices, complex generics and differentiated products | Track R&D spend as a percentage of revenue and product pipeline updates |
| Manufacturing and quality | Pharma companies depend on compliant plants and reliable supply chains | Regulatory observations from USFDA or other authorities are key monitorables |
| Access and affordability | Cipla has a long healthcare access positioning across essential medicines | Useful for brand trust, but investors should still evaluate financial discipline |
Ratios help retail investors compare Cipla with its own history and with pharma peers. A single ratio should never be used alone; combine valuation ratios with growth, quality, margins, regulation and cash flow.
| Metric | Value | Beginner interpretation |
|---|---|---|
| Trailing P/E | — | Use with earnings growth and risk context |
| Price to Book | — | Compare with pharma peer group and return ratios |
| Return on Equity | — | Shows profit generated on shareholder equity |
| Operating Margin | — | Useful for tracking pricing power and cost control |
| Gross Margin | — | Important in pharmaceutical manufacturing and product mix |
| Debt to Equity | — | Lower leverage can provide flexibility, but verify from filings |
| Dividend Yield | — | Trailing yield; verify latest declared dividend |
| EPS TTM | — | Trailing earnings per share |
Cipla is often compared with large Indian pharmaceutical companies. Peer comparison should consider therapy mix, India business strength, US generics exposure, regulatory history, product pipeline, margins, return ratios and valuation.
| Company | Market Cap | Price | P/E | P/B | Dividend Yield | Volume |
|---|---|---|---|---|---|---|
| Cipla Ltd | Live feed | Live feed | Live feed | Live feed | Live feed | Live feed |
| Sun Pharmaceutical Industries Ltd | Verify | Verify | Verify | Verify | Verify | Verify |
| Dr. Reddy's Laboratories Ltd | Verify | Verify | Verify | Verify | Verify | Verify |
| Divi's Laboratories Ltd | Verify | Verify | Verify | Verify | Verify | Verify |
| Lupin Ltd | Verify | Verify | Verify | Verify | Verify | Verify |
| Torrent Pharmaceuticals Ltd | Verify | Verify | Verify | Verify | Verify | Verify |
Peer data from live quote feeds may be delayed. Verify market cap, valuation multiples and corporate actions from official exchange and company sources.
Dividends, bonus issues and stock splits are corporate actions that can affect shareholder records and price charts. They do not by themselves decide investment quality, so always review profit growth, free cash flow and capital allocation along with corporate action history.
| Action | Detail | Date / Note |
|---|---|---|
| Dividend | ₹13.00 per share | 05 Jun 2026 |
| Dividend | ₹16.00 per share | 27 Jun 2025 |
| Dividend | ₹13.00 per share | 02 Aug 2024 |
| Dividend | ₹8.50 per share | 21 Jul 2023 |
| Investor note | Do not rely only on third-party summaries | Always verify dividend, bonus and split details from official NSE/BSE/company announcements |
Important: verify the latest dividend amount, ex-date, record date, payment date, bonus ratio, split ratio and face value from Cipla investor relations, NSE corporate actions and BSE filings before acting.
Cipla can benefit from strong healthcare demand, branded medicines, respiratory products, complex generics and international opportunities. At the same time, pharmaceutical stocks can be affected by regulatory inspections, price controls, product delays, competition, currency movement and sudden changes in product profitability.
| Monitorable | Why it matters | Where to verify |
|---|---|---|
| Regulatory inspections | Observations or warning letters can affect product approvals and supply | Company announcements, USFDA updates, NSE/BSE filings |
| India business growth | India formulations are important for recurring prescription-led revenue | Quarterly results, investor presentations |
| North America launches | US generics and complex products can drive growth but face price erosion | Quarterly commentary, product approval updates |
| Margins and R&D spend | Margins show pricing and cost control, while R&D supports future launches | Financial results and annual report |
| Cash flow and debt | Cash generation supports dividends, acquisitions and reinvestment | Cash flow statement and balance sheet |
| Corporate actions | Dividends, bonuses and splits affect shareholder records and price adjustment | NSE, BSE and company filings |
These FAQs answer common AI-search-style questions about Cipla share price, company profile, products, business model, financials, risks, dividends and investment monitorables. They are educational and do not provide buy or sell recommendations.
Cipla Ltd is an Indian pharmaceutical company that develops, manufactures and markets medicines across therapy areas such as respiratory care, anti-infectives, HIV/AIDS, urology, oncology, cardio-metabolic care, central nervous system, consumer health and other chronic and acute treatments.
Cipla trades on the National Stock Exchange with the symbol CIPLA and on BSE with the code 500087. For live market data on this page, the Yahoo Finance-compatible symbol used is CIPLA.NS.
You can track the Cipla live share price through the live quote area and interactive chart on this page. Prices can be delayed or temporarily unavailable, so investors should also cross-check live quotes on NSE, BSE, broker platforms or official market data sources.
The 52 week high is the highest traded price in the previous one-year period, while the 52 week low is the lowest traded price in the same period. These levels help beginners understand the recent price range, but they should not be used alone for investment decisions.
Cipla earns revenue by selling branded prescription medicines, trade generics, complex generics, respiratory products, active pharmaceutical ingredients, consumer health products and other pharmaceutical products in India and international markets including North America, South Africa and other emerging markets.
Important areas to monitor include India branded prescription products, trade generics, respiratory therapies, North America generics and complex products, South Africa and global access markets, emerging markets, consumer health and active pharmaceutical ingredients. Investors should verify the latest segment reporting in Cipla annual reports and exchange filings.
Cipla is widely associated with respiratory care and inhalation products, along with therapies in HIV/AIDS, anti-infectives, urology, oncology, cardiology, diabetes, dermatology, central nervous system care and consumer wellness. Product availability and brand names vary by market and regulation.
Cipla has a strong presence in generics and branded generics, but it also works across complex generics, respiratory devices, specialty products, consumer health and active pharmaceutical ingredients. This mix makes its business broader than a simple generic medicines model.
Key risks include regulatory observations from drug authorities, pricing pressure in generic markets, currency movement, product concentration in certain therapies, supply chain disruption, litigation, competition, raw material costs and delays in product approvals. Always read the risk section of the latest annual report before making decisions.
Cipla has paid dividends in various years, but dividend amount, record date and payment date can change every year. Investors should verify the latest dividend declaration from company announcements, NSE filings and BSE filings before relying on any dividend information.
Bonus and split details should always be checked from official exchange corporate action records. This page is educational and investors should verify the latest bonus, split, face value and record date information from NSE, BSE or Cipla investor relations.
Beginners can monitor revenue growth, EBITDA margin, net profit, earnings per share, return on equity, return on capital employed, debt level, free cash flow, research and development spend, working capital, product approvals and geographic revenue mix.
Cipla can be compared with large Indian pharmaceutical peers on revenue growth, margins, valuation multiples, product pipeline, US generics exposure, India branded business, regulatory track record, return ratios, dividend record and balance sheet strength.
The latest Cipla shareholding pattern should be verified from NSE, BSE and company investor relations filings. Shareholding can change every quarter, especially for foreign institutions, mutual funds, insurance companies and public shareholders.
No. This page is for education, company understanding and market tracking only. It does not provide buy, sell or hold recommendations. Retail investors should do independent research or consult a SEBI-registered adviser before making investment decisions.
